Rankings
▼
Calendar
UTHR Q3 2021 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q3 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$445M
+17.0% YoY
Gross Profit
$417M
93.8% margin
Operating Income
$229M
51.4% margin
Net Income
$163M
36.6% margin
EPS (Diluted)
$3.42
QoQ Revenue Growth
-0.4%
Cash Flow
Operating Cash Flow
$186M
Free Cash Flow
$162M
Stock-Based Comp.
$25M
Balance Sheet
Total Assets
$5.0B
Total Liabilities
$1.2B
Stockholders' Equity
$3.8B
Cash & Equivalents
$909M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$445M
$380M
+17.0%
Gross Profit
$417M
$356M
+17.1%
Operating Income
$229M
$221M
+3.4%
Net Income
$163M
$171M
-5.0%
Revenue Segments
Tyvaso
$164M
37%
Remodulin
$125M
28%
Orenitram
$85M
19%
Unituxin
$55M
12%
Adcirca
$15M
3%
Geographic Segments
UNITED STATES
$412M
93%
European Union And Others
$33M
7%
← FY 2021
All Quarters
Q4 2021 →